title: Biomarkers for EGFR-antagonist response: in the genes and on the genes!
abstract: Patients with non-small cell lung carcinoma containing epidermal growth factor receptor (EGFR)-activating mutations benefit from EGFR-antagonist therapy. EGFR-antagonist sensitivity is also correlated with epithelial-mesenchymal transition, which Walter and colleagues show to be marked by DNA-methylation changes. If validated, these markers could help identify patients with wild-type EGFR who will benefit from EGFR therapy.
authors.affiliation: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. heaswar2@jhmi.edu
authors.forename: Hariharan
authors.initials: H
authors.lastname: Easwaran
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Baylin
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000145:classification* / Q000235:genetics*; D019175:DNA Methylation / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification* / Q000235:genetics*